Pneumagen


Illetrop provides hands-on senior executive support to biotechnology companies. Based in Scotland but operating internationally, Illetrop represents a number of companies from the UK, Asia and mainland Europe including Pneumagen a company focused on developing glycan targeted carbohydrate binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs). Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology. Pneumagen has spun-off, through a demerger, a separate company called Omideon Limited. Omideon is focused on progressing the research and development of mCBMs in oncology . Please visit the website for more information. www.omideon.com

Contact Pneumagen via their website


News archive

05/10/2020   Pneumagen‘s anti COVID-19 Neumifil featured in SCRIP‘s 10 to WATCH...more

16/09/2020   Pneumagen Announces Scientific Advisory Board and Development Team Appointments...more

27/05/2020   Pneumagen Announces £4m fundraising and Commits to Covid–19 Trial Development...more

08/05/2020   Pneumagen‘s Recent Covid–19 Data Covered by BBC‘s ”The Nine”...more

28/04/2020   PneumagenAnnounces Positive Anti–Viral Activity for Covid–19 Novel Glycan Approach...more

17/03/2020   Pneumagen Leverages Novel Glycan Approach to Target Covid–19...more

12/11/2019   Pneumagen Presents Poster on a Novel Preventative and Treatment of RSV...more

15/10/2019   Pneumagen Demonstrates Preclinical Proof–of–Concept in Oncology for Neumonco...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code